The latest new contracts, like Transgene’s — who’s behind them and what they mean, delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Transgene and ProBioGen Enter Partnership for Cancer Vaccine Development
Nov 05, 2024•over 1 year ago
Contract Type
partnership
Bas-RhinBiotechnologyHealth CareTherapeutics
Description
Transgene and ProBioGen have entered into a partnership to advance individualized cancer vaccine development. The partnership aims to combine ProBioGen's specific production technology with the manufacturing capabilities of Transgene's individualized cancer vaccine program and its myvac® platform.
Company Information
Company
Transgene
Location
Bas-Rhin, Grand Est, France
About
Transgene is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. The Company’s clinical-stage programs consist of a portfolio of therapeutic vaccines and oncolytic viruses with the goal of indirectly or directly killing cancer cells.